Meeder Asset Management’s CASI Pharmaceuticals CASI Stock Holding History

Meeder Asset Management’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-407	Closed	-$5K	–	1343
2021 Q3	$5K	Hold	407	–	–	﹤0.01%	1914
2021 Q2	$6K	Hold	407	–	–	﹤0.01%	1864
2021 Q1	$10K	Buy	+407	New	+$11.4K	﹤0.01%	1598
2020 Q4	–	Sell	-133	Closed	-$2K	–	1909
2020 Q3	$2K	Hold	133	–	–	﹤0.01%	1809
2020 Q2	$3K	Hold	133	–	–	﹤0.01%	1648
2020 Q1	$3K	Buy	133 +89	+202%	+$2.12K	﹤0.01%	1933
2019 Q4	$1K	Sell	44 -491	-92%	-$15.9K	﹤0.01%	2116
2019 Q3	$18K	Buy	+535	New	+$17.2K	﹤0.01%	1345
2019 Q1	–	Sell	-958	Closed	-$38K	–	1712
2018 Q4	$38K	Buy	958 +372	+63%	+$14.1K	﹤0.01%	885
2018 Q3	$28K	Buy	+586	New	+$40.9K	﹤0.01%	944

Other funds holding CASI

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Meeder Asset Management's CASI Position: Q4 2021 in Review

Meeder Asset Management sold out of CASI Pharmaceuticals (CASI) in Q4 2021, closing a stake of 407 shares — an estimated $5K sold.

Meeder Asset Management first reported a position in CASI in Q3 2018 and held it in 10 quarters. The position peaked at $38K in Q4 2018. 51 funds tracked by Wall St. Rank hold CASI as of Q4 2021.

Meeder Asset Management reported no remaining CASI Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Meeder Asset Management sold 407 CASI Pharmaceuticals shares in Q4 2021, an estimated $5K.
Meeder Asset Management first reported a position in CASI Pharmaceuticals in Q3 2018 and held it in 10 quarters.
Meeder Asset Management's CASI Pharmaceuticals position peaked at $38K in Q4 2018.
51 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.